Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04191941 | Treatment of Hematological Malignancy With Novel CAR-T Cells. | unknown | Early Phase 1 | 9 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04184414 | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2019 |
| NCT02268370 | Treatment-free Remission Accomplished With Dasatinib in Patients With CML(TRAD) | unknown | Phase 2 | 131 | University Health Network, TorontoOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04175587 | Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL(RIF) | unknown | Phase 3 | 109 | Peking University People's HospitalOTHER | 0 | Nov 29, 2019 | clinicaltrials |
| NCT03110640 | Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | unknown | Phase 1 | 20 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT03260101 | Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study | unknown | — | 12 | Cellect BiotechnologyINDUSTRY | 1 | Nov 26, 2019 | clinicaltrials |
| NCT04168138 | D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients | unknown | N/A | 20 | Huihan WangOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT04166838 | The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) | unknown | Early Phase 1 | 20 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04156178 | CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156243 | CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156256 | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04158011 | A Retrospective Study of Patients With Leukemia Relapse in the CNS Treated With CAR T Cells | unknown | — | 80 | Sheba Medical CenterOTHER_GOV | 1 | Nov 8, 2019 | clinicaltrials |
| NCT04150471 | Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients | unknown | — | 79 | Seoul St. Mary's HospitalOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT03836690 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation(ToTem) | unknown | Phase 1 | 18 | University College, LondonOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02619630 | Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)(GRAALL-2014/T) | unknown | Phase 2 | 275 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT04133220 | Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid Leukemia(HEAL) | unknown | — | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 21, 2019 | clinicaltrials |
| NCT02809092 | Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 30 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Oct 15, 2019 | clinicaltrials |
| NCT04120896 | Karate or Kung Fu? | unknown | N/A | 52 | The University of Hong KongOTHER | 1 | Oct 9, 2019 | clinicaltrials |
| NCT03907670 | Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor | unknown | — | 45 | Assiut UniversityOTHER | 0 | Sep 30, 2019 | clinicaltrials |
| NCT04104035 | Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response | unknown | — | 100 | Ankara UniversityOTHER | 1 | Sep 27, 2019 | clinicaltrials |
| NCT04028440 | γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | unknown | Early Phase 1 | 6 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT04096846 | Effect of Vitamin D Diffiency on Oral Mucosa in Patients Recieving Methotrexate Chemotherapy(VitDandMTX) | unknown | — | 100 | Assiut UniversityOTHER | 0 | Sep 20, 2019 | clinicaltrials |
| NCT04094051 | Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice | unknown | — | 580 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT04087967 | Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients | unknown | Phase 3 | 162 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT04083911 | Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 | unknown | Phase 3 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT04084327 | Immunophenotyping of Acute b Cell Lymphoblstic Leukemia | unknown | — | 50 | South Egypt Cancer InstituteOTHER | 0 | Sep 10, 2019 | clinicaltrials |
| NCT03910842 | Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy | unknown | Early Phase 1 | 12 | Timmune Biotech Inc.INDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT04074213 | Clozapine and Haematologic Malignancies: Observational and Retrospective Study Using the WHO Pharmacovigilance Database(CLOZARIX) | unknown | — | 1,000,000 | University Hospital, CaenOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT03181815 | Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03318419 | Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT01987297 | Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL | unknown | Phase 4 | 738 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT04060485 | Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results | unknown | — | 1,000 | National Taiwan University HospitalOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT03598179 | XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects | unknown | Phase 2 | 10 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04007978 | Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies | unknown | Phase 1 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04008251 | Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | unknown | Phase 1 | 10 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04008381 | Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia | unknown | Phase 1 | 38 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04043676 | Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia | unknown | Phase 2 | 40 | Fundación Teófilo Hernando, SpainOTHER | 1 | Aug 2, 2019 | clinicaltrials |
| NCT00550992 | Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia(Interfant06) | unknown | N/A | 445 | Dutch Childhood Oncology GroupOTHER | 9 | Jul 30, 2019 | clinicaltrials |
| NCT03062436 | To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission | unknown | N/A | 27 | Command Hospital, IndiaOTHER_GOV | 1 | Jul 23, 2019 | clinicaltrials |
| NCT03913312 | Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML | unknown | Phase 1 / Phase 2 | 150 | Ruijin HospitalOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT04024241 | Medium Dose of Cytarabine and Mitoxantrone(HAM) | unknown | — | 250 | Shenzhen People's HospitalOTHER | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | unknown | Phase 1 / Phase 2 | 65 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT04015024 | A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT04012879 | Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia | unknown | Phase 1 | 12 | Chinese PLA General HospitalOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT03337568 | Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission(AML_AlloHCT) | unknown | — | 110 | Asan Medical CenterOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT04008888 | a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients | unknown | N/A | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT03885076 | Gamma Delta T Cells in AML | unknown | — | 20 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 2, 2019 | clinicaltrials |
| NCT02349698 | A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02710149 | A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Dec 10, 2019source: clinicaltrials